ArticleFASEB bioAdvances2025
Folic Acid Supplementation Attenuates Hepatic Steatosis by Enhancing Choline Availability and Remodeling Fatty Acid Profiles in Mice Fed a High-Fat Diet.
Article in FASEB bioAdvances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early-Life Nutritional Determinants of Pediatric MASLD.Nutrients · 2025Review
- Folic Acid Supplementation Attenuates Hepatic Steatosis by Enhancing Choline Availability and Remodeling Fatty Acid Profiles in Mice Fed a High-Fat Diet.FASEB bioAdvances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-fat diets (HFDs) are a well-established cause of hepatic steatosis, a condition associated with altered hepatic fatty acid metabolism and reduced choline availability. Folic acid (FA) deficiency can also promote steatosis, in part by impairing choline metabolism. Although FA supplementation has been found to reduce liver fat in mice with hepatic steatosis, it is unclear if this effect is due to increased hepatic choline levels, changes in fatty acid profiles, or a combination of both. In this study, four-week-old male C57BL/6J mice were fed 45 kcal% HFDs with total FA content adjusted to onefold, fivefold, or tenfold AIN-93G recommended level (2 mg/kg diet) for 15 weeks ad libitum. Hepatic triacylglycerol (TAG), choline concentrations, expression of key genes in choline metabolism, and TAG-bound fatty acid profiles were analyzed. Mice receiving tenfold FA had lower liver weight and hepatic TAG levels compared to the onefold control group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.